临床病理学和免疫组织化学风险预测因子对氨基母细胞瘤复发的预测
Hévila de Figueiredo Pires1, Glória Maria de França2, Hannah Gil de Farias Morais2
1Department of Oral Pathology, Federal University of Rio Grande do Norte, Av. Senador Salgado Filho, Lagoa Nova, Natal, RN, 1787, CEP 59056-000, Brazil. hevilapires@gmail.com.
Head and neck pathology
|February 17, 2025
概括
复发性乳腺母细胞瘤 (AMB) 与特定的临床病理特征和不匹配修复蛋白质的损失有关,人类Mut-L同源1 (hMLH1) 和人类Mut-L同源2 (hMSH2). 这些因素可以预测AMB的复发.
科学领域:
- 在瘤学瘤学.
- 口腔和牙面部外科手术
- 分子病理学分子病理学
背景情况:
- 骨髓母细胞瘤 (AMB) 是一种具有高复发率的局部侵袭性牙瘤.
- 了解复发的预测因素对于有效的管理和改善患者结果至关重要.
研究的目的:
- 调查临床病理学和免疫组织化学变量与乳腺母细胞瘤复发之间的关联.
- 具体来说,分析人类Mut-L同源1 (hMLH1) 和人类Mut-L同源2 (hMSH2) 在复发性和非复发性AMBs中的表达.
主要方法:
- 一项追溯的观察病例控制研究,涉及44例AMB病例 (22例复发,22例非复发),随访时间超过一年.
- 对hMLH1和hMSH2核表达的定量免疫组织化学分析.
- 统计分析包括麦克纳马测试,卡普兰-梅尔生存分析和日志等级测试.
主要成果:
- 后下是复发性和非复发性AMBs最常见的地方.
- 与AMB复发显著相关的因素包括皮质骨扩张,缺少骨重建,保守治疗,hMSH2和hMLH1免疫表达的丧失以及强大的Ki-67免疫表达.
- 复发的重大风险因素包括解剖位置,局部性,皮质扩张,皮质穿孔,骨吸收,牙冲击,部重建以及hMSH2和hMLH1.1的免疫表达减少.
结论:
- 放射性外观,治疗方式和不匹配修复蛋白的免疫表达 (hMLH1和hMSH2) 是AMB复发的重要预测因素.
- 这些发现可以帮助识别高风险病例,并定制治疗策略,以尽量减少复发.
相关概念视频
01:26Factors Affecting the Risk of Infection
The hosts' susceptibility to infection depends on several factors. The integrity of the skin and mucous membranes helps protect the body against microbial attacks. When the skin is altered, the chance of infection, limb loss, and even death increases.
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin create...
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...